Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 19, Pages 4926
Publisher
MDPI AG
Online
2021-09-30
DOI
10.3390/cancers13194926
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
- (2021) Gregory J. Riely et al. Cancer Discovery
- HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
- (2021) Kimio Yonesaka Cancers
- Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
- (2021) Arsela Prelaj et al. EUROPEAN JOURNAL OF CANCER
- Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
- (2021) Ira W. Deveson et al. NATURE BIOTECHNOLOGY
- Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
- (2021) Tereza Vaclova et al. Nature Communications
- Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
- (2021) Mihaela Aldea et al. Cancer Discovery
- First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2021) Qiang Wu et al. Frontiers in Oncology
- First-Line Afatinib plus Cetuximab for EGFR-Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study
- (2021) Alexis B. Cortot et al. CLINICAL CANCER RESEARCH
- Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
- (2021) Kenneth K. W. To et al. Frontiers in Oncology
- Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
- (2020) Kari J. Kurppa et al. CANCER CELL
- Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
- (2020) Adam J Schoenfeld et al. CLINICAL CANCER RESEARCH
- Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
- (2020) Danielle Cohen et al. Journal of Thoracic Oncology
- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- (2020) Lecia V Sequist et al. LANCET ONCOLOGY
- Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
- (2020) Chunhua Ma et al. Frontiers in Oncology
- Sequencing Strategies for Fusion Gene Detection
- (2020) Erin E. Heyer et al. BIOESSAYS
- Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer
- (2020) Jiyun Lee et al. CANCER
- The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
- (2020) Valerio Gristina et al. CANCER TREATMENT REVIEWS
- Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
- (2020) Zofia Piotrowska et al. CLINICAL CANCER RESEARCH
- Reduced sensitivity for EGFR T790M mutations using the Idylla EGFR Mutation Test
- (2020) Eric Lee et al. JOURNAL OF CLINICAL PATHOLOGY
- PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy
- (2020) Kaiyan Chen et al. LUNG CANCER
- Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
- (2020) Junji Tsurutani et al. Cancer Discovery
- HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
- (2020) Bob T. Li et al. Cancer Discovery
- Mechanisms of resistance to osimertinib
- (2020) Chiara Lazzari et al. Journal of Thoracic Disease
- Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
- (2020) Yi-Long Wu et al. Lancet Respiratory Medicine
- Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
- (2020) Matteo Canale et al. Journal of Clinical Medicine
- Clinical impacts of EGFR mutation status: analysis of 5,780 surgically resected lung cancer cases
- (2020) Kenichi Suda et al. ANNALS OF THORACIC SURGERY
- Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC
- (2020) Ibiayi Dagogo-Jack et al. Journal of Thoracic Oncology
- Amivantamab (JNJ-61186372), An Fc Enhanced EGFR/cMet Bispecific Antibody Induces Receptor Downmodulation And Anti-tumor Activity By Monocyte/Macrophage Trogocytosis
- (2020) Smruthi Vijayaraghavan et al. MOLECULAR CANCER THERAPEUTICS
- Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance
- (2020) Swastika Maity et al. Pharmacological Reports
- Transcriptomic silencing as a potential mechanism of treatment resistance
- (2020) Jacob J. Adashek et al. JCI Insight
- Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review
- (2020) Rossella Bruno et al. Diagnostics
- 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
- (2020) S.S. Schalm et al. ANNALS OF ONCOLOGY
- Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
- (2020) Laura Keller et al. BRITISH JOURNAL OF CANCER
- Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice
- (2020) Charu Aggarwal et al. Nature Reviews Clinical Oncology
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study
- (2020) Pierre-Jean Lamy et al. Cancers
- Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay
- (2020) Yassine Belloum et al. Cells
- PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
- (2020) H. Blons et al. LUNG CANCER
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers
- (2019) Morana Vojnic et al. Journal of Thoracic Oncology
- Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib
- (2019) Annie W. Nelson et al. Journal of Thoracic Oncology
- Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC
- (2019) Ibiayi Dagogo-Jack et al. Journal of Thoracic Oncology
- Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
- (2019) Alessandro Russo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation
- (2019) Benjamin P Brown et al. CLINICAL CANCER RESEARCH
- Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium
- (2019) B T Li et al. ANNALS OF ONCOLOGY
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Ultra-sensitive EGFRT790Mdetection as an independent prognostic marker for lung cancer patients harboring EGFRdel19mutations and treated with first-generation TKIs
- (2019) Julie vendrell et al. CLINICAL CANCER RESEARCH
- High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden
- (2019) Ryma Benayed et al. CLINICAL CANCER RESEARCH
- Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
- (2019) Silvia La Monica et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC
- (2019) Paola Bordi et al. LUNG CANCER
- Concurrent EGFR‐TKI and Thoracic Radiotherapy as First‐Line Treatment for Stage IV Non‐Small Cell Lung Cancer Harboring EGFR Active Mutations
- (2019) LinPeng Zheng et al. ONCOLOGIST
- Single and dual targeting of mutant EGFR with an allosteric inhibitor
- (2019) Ciric To et al. Cancer Discovery
- Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms
- (2019) James P. Solomon et al. CANCER RESEARCH
- Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
- (2019) Michael Offin et al. Journal of Thoracic Oncology
- RNA sequencing: the teenage years
- (2019) Rory Stark et al. NATURE REVIEWS GENETICS
- An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer
- (2019) Brian C. Haynes et al. Translational Oncology
- Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
- (2019) Santoni-Rugiu et al. Cancers
- Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
- (2019) Tianli Zhang et al. Translational Lung Cancer Research
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
- (2019) Jhanelle E. Gray et al. CLINICAL CANCER RESEARCH
- EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples
- (2019) Deepa Rangachari et al. Journal of Thoracic Oncology
- Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA
- (2019) Julianna G. Supplee et al. LUNG CANCER
- Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
- (2019) Peter T Harrison et al. SEMINARS IN CANCER BIOLOGY
- Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer
- (2019) Vassiliki A. Papadimitrakopoulou et al. CANCER
- Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives
- (2019) Sara Elena Rebuzzi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib Therapy
- (2019) H. Yu et al. Journal of Thoracic Oncology
- Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study
- (2019) Camille Mehlman et al. LUNG CANCER
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Simultaneous Detection of Gene Fusions and Base Mutations in Cancer Tissue Biopsies by Sequencing Dual Nucleic Acid Templates in Unified Reaction
- (2019) Zhengbo Song et al. CLINICAL CHEMISTRY
- Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
- (2019) Jang Ho Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib
- (2019) Wenfeng Fang et al. Journal of Thoracic Oncology
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Kazuhiko Nakagawa et al. LANCET ONCOLOGY
- Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project
- (2019) Michèle Beau-Faller et al. LUNG CANCER
- Evaluation of the Idylla system to detect the EGFR mutation using extracted DNA
- (2019) Claire Bocciarelli et al. PATHOLOGY RESEARCH AND PRACTICE
- Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
- (2018) C Ricordel et al. ANNALS OF ONCOLOGY
- Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer
- (2018) N Guibert et al. ANNALS OF ONCOLOGY
- Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma
- (2018) Stéphane Renaud et al. ANNALS OF SURGICAL ONCOLOGY
- Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?
- (2018) Greta Alì et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants
- (2018) Cristina Teixidó et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
- (2018) Sun Min Lim et al. CANCER TREATMENT REVIEWS
- Clinical Utility of Cell-Free DNA for the Detection ofALKFusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2018) Caroline E. McCoach et al. CLINICAL CANCER RESEARCH
- Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
- (2018) Zhe Yang et al. CLINICAL CANCER RESEARCH
- Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
- (2018) Dana Wai Yi Tsui et al. EMBO Molecular Medicine
- Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform
- (2018) Kenneth T.E. Chang et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
- (2018) Travis A. Clark et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors
- (2018) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR- Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study
- (2018) Giorgio V. Scagliotti et al. Journal of Thoracic Oncology
- Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples
- (2018) Kurtis D. Davies et al. Journal of Thoracic Oncology
- EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib
- (2018) Qi Zhang et al. Journal of Thoracic Oncology
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
- (2018) R. Minari et al. LUNG CANCER
- Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
- (2018) Nicolas Floc'h et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
- (2018) Jacqulyne P. Robichaux et al. NATURE MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples
- (2018) Stine H. Kresse et al. PLoS One
- Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients
- (2018) Claudia Vollbrecht et al. Oncotarget
- Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
- (2018) Chia-Chi Lin et al. Lancet Respiratory Medicine
- Common Co-activation of AXL and CDCP1 in EGFR -mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
- (2018) Niki Karachaliou et al. EBioMedicine
- Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study
- (2018) Cecily P. Vaughn et al. BMC CANCER
- Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
- (2018) Ilaria Attili et al. Expert Review of Anticancer Therapy
- AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells
- (2018) Zhirui Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
- (2018) Yi-Long Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma
- (2018) Tyler E Miller et al. JOURNAL OF CLINICAL PATHOLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry
- (2018) Xiaoyun Lu et al. MEDICINAL RESEARCH REVIEWS
- Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI
- (2018) Chien-Hui Weng et al. ONCOGENE
- Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
- (2018) Zachary A. Yochum et al. ONCOGENE
- Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.
- (2018) Zofia Piotrowska et al. Cancer Discovery
- The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
- (2018) Francesco Passiglia et al. Scientific Reports
- Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
- (2018) Geoffrey R. Oxnard et al. JAMA Oncology
- 1381PDGefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study
- (2018) J C-H Yang et al. ANNALS OF ONCOLOGY
- LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
- (2018) V A Papadimitrakopoulou et al. ANNALS OF ONCOLOGY
- LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
- (2018) S S Ramalingam et al. ANNALS OF ONCOLOGY
- Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing
- (2018) Shinji Kohsaka et al. Future Oncology
- EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
- (2018) Nicolas Marcoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
- (2018) Yan Zhang et al. OncoTargets and Therapy
- Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer
- (2018) Charu Aggarwal et al. JAMA Oncology
- Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
- (2018) Sha Zhao et al. LUNG CANCER
- Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
- (2017) June-Koo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
- (2017) Tony S.K. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
- (2017) Silvia La Monica et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
- (2017) Zhen Wang et al. Journal of Thoracic Oncology
- Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2017) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France
- (2017) Nicolas Guibert et al. Journal of Thoracic Oncology
- Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
- (2017) Chao-Chi Ho et al. Journal of Thoracic Oncology
- Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer
- (2017) Surein Arulananda et al. Journal of Thoracic Oncology
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
- (2017) A. Oztan et al. LUNG CANCER
- Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC
- (2017) Franciele H. Knebel et al. LUNG CANCER
- Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
- (2017) Catherine Labbé et al. LUNG CANCER
- Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib
- (2017) Sai-Hong Ignatius Ou et al. LUNG CANCER
- The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing
- (2017) Jérôme Alexandre Denis et al. Molecular Diagnosis & Therapy
- Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
- (2017) Matthew J. Hangauer et al. NATURE
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
- (2017) Collin M Blakely et al. NATURE GENETICS
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
- (2017) Shinji Kohsaka et al. Science Translational Medicine
- Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
- (2017) Ken Uchibori et al. Nature Communications
- EGFR G796D mutation mediates resistance to osimertinib
- (2017) Di Zheng et al. Oncotarget
- Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes
- (2017) Kentaro Inamura et al. Oncotarget
- Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
- (2017) Lin Li et al. Oncotarget
- Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
- (2017) Rafael Rosell et al. Lancet Respiratory Medicine
- Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEX® HS, a new highly sensitive assay for the MassARRAY® System
- (2017) Bobbie C. Sutton et al. PLoS One
- Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
- (2016) Puyu Shi et al. CANCER LETTERS
- Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommonepidermal growth factor receptormutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
- (2016) Eri Banno et al. CANCER SCIENCE
- Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
- (2016) Yoshihisa Kobayashi et al. CANCER SCIENCE
- Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
- (2016) J. C. Thompson et al. CLINICAL CANCER RESEARCH
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- (2016) S. Ortiz-Cuaran et al. CLINICAL CANCER RESEARCH
- Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
- (2016) Matteo Canale et al. CLINICAL CANCER RESEARCH
- The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
- (2016) Olivier Calvayrac et al. EMBO Molecular Medicine
- Advances in clinical next-generation sequencing: target enrichment and sequencing technologies
- (2016) Leomar Y. Ballester et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
- (2016) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel EGFR C797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next-Generation Sequencing Assay
- (2016) Roopika Menon et al. Journal of Thoracic Oncology
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
- (2016) Glenwood Goss et al. LANCET ONCOLOGY
- Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
- (2016) Li-Yang Chen et al. LUNG CANCER
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
- (2016) Yong Jia et al. NATURE
- A framework for understanding and targeting residual disease in oncogene-driven solid cancers
- (2016) Trever G Bivona et al. NATURE MEDICINE
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells
- (2016) Yaqiong Tian et al. ONCOLOGY RESEARCH
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
- (2015) D. Planchard et al. ANNALS OF ONCOLOGY
- First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
- (2015) Y.-L. Wu et al. ANNALS OF ONCOLOGY
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
- (2015) C. A. Eberlein et al. CANCER RESEARCH
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
- (2015) D. Ercan et al. CLINICAL CANCER RESEARCH
- Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
- (2015) Juliana Eng et al. Journal of Thoracic Oncology
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
- (2015) Kenneth S. Thress et al. LUNG CANCER
- Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification
- (2015) Noëlle Weingertner et al. PATHOLOGY
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
- (2015) Matthew J. Niederst et al. Nature Communications
- In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
- (2015) Toshiyuki Hirano et al. Oncotarget
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
- (2014) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung
- (2014) H.-U. Schildhaus et al. CLINICAL CANCER RESEARCH
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- (2014) Takashi Seto et al. LANCET ONCOLOGY
- Anchored multiplex PCR for targeted next-generation sequencing
- (2014) Zongli Zheng et al. NATURE MEDICINE
- Sequencing depth and coverage: key considerations in genomic analyses
- (2014) David Sims et al. NATURE REVIEWS GENETICS
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
- (2014) E. C. de Bruin et al. Cancer Discovery
- Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
- (2013) M. Beau-Faller et al. ANNALS OF ONCOLOGY
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- (2013) J-Y Douillard et al. BRITISH JOURNAL OF CANCER
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
- (2013) Jacques Cadranel et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
- (2013) M. E. Arcila et al. MOLECULAR CANCER THERAPEUTICS
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
- (2013) H. Yasuda et al. Science Translational Medicine
- Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
- (2012) A. Inoue et al. ANNALS OF ONCOLOGY
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2012) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib
- (2012) Sandra P. D’Angelo et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
- (2011) J. Chmielecki et al. Science Translational Medicine
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
- (2011) A. C. Faber et al. Cancer Discovery
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
- (2010) Geoffrey R. Oxnard et al. CLINICAL CANCER RESEARCH
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More